Myriad Genetics, Inc. and telehealth provider Gabbi have announced a strategic collaboration to enhance access to hereditary cancer risk assessment tools, combining their respective expertise in genetic testing and breast cancer risk evaluation services.
The partnership integrates Myriad's MyRisk with RiskScore Hereditary Cancer Test into Gabbi's telehealth platform, creating a comprehensive solution for breast cancer risk assessment and specialist care services. This integration enables seamless access to genetic testing for patients identified as potentially high-risk through Gabbi's initial screening process.
Clinical Impact and Patient Benefits
The collaboration's significance is underscored by the MyRisk with RiskScore test's demonstrated clinical utility. According to Myriad Genetics, 53% of patients who undergo testing qualify for modifications in their medical management plans, including increased surveillance through more frequent mammograms or MRI imaging.
"Genetic testing is a crucial aspect of assessing a woman's risk and highly informs her care," said Kaitlin Christine, Founder and CEO of Gabbi, who brings personal insight to the mission, having lost her mother to breast cancer and faced her own diagnosis. "The gold-standard MyRisk with RiskScore Hereditary Cancer Test delivers clear, actionable results, which can become the foundation for a personalized care plan."
Comprehensive Care Coordination
Gabbi's platform provides immediate access to clinical breast specialists who can evaluate patients for genetic testing eligibility and develop personalized risk management strategies. The service includes:
- Same-day consultations with clinicians
- Risk assessment and evaluation
- Development of personalized action plans
- Coordination of necessary imaging and testing
- Ongoing care navigation support
"Hereditary cancer risk assessment may provide peace of mind and help inform access to early detection screening tools for women at an elevated risk for cancer," explained Melissa Gonzales, President of Myriad Women's Health. "We fully support Gabbi's mission to empower women to better understand their risk of breast cancer and make informed health decisions."
Technology-Enabled Risk Assessment
The integrated offering leverages Gabbi's telehealth infrastructure to streamline the genetic testing process. Patients identified as potentially high-risk through initial screening are seamlessly connected with Gabbi clinicians who can evaluate the need for Myriad's MyRisk Hereditary Cancer Test.
This technology-enabled approach aims to remove barriers to access while ensuring appropriate clinical oversight and support throughout the risk assessment journey. The collaboration represents a significant step forward in making comprehensive cancer risk assessment more accessible to women who could benefit from enhanced screening and preventive care measures.
